Seeking Alpha

GlaxoSmithKline (GSK) will take a pharma-record £2.2B ($3.5B) charge in the fourth quarter...

GlaxoSmithKline (GSK) will take a pharma-record £2.2B ($3.5B) charge in the fourth quarter to settle lawsuits and regulatory fines related to past sales practices. The sum outstrips Pfizer's (PFE) 2009 payment of $2.3B and relates mostly to practices between 1997 and 2004, including those around antidepressants Paxil and Wellbutrin and former diabetes blockbuster Avandia.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs